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T-Cell Manufacture for Treatment of Acute Lymphoblastic Leukemia
Abstract
Adoptive T-cell therapy is a recent medical development that has shown clinical success in treating
relapsed acute lymphoblastic leukemia (ALL), a common form of cancer with a poor prognosis. Ironically,
the treatment’s greatest advantage is at the same time deterring large pharmaceutical companies from
commercializing it. Adoptive T-cell therapy is successful in treating ALL largely because it takes a
patient’s own cells and engineers them to fight the cancer. While the autologous nature of the treatment
helps to incorporate the engineered T-cells into the patient’s body, it also makes each treatment patientspecific. This does not fit into the paradigm of large pharmaceutical companies, who want “off the shelf”
drugs. Critics claim that adoptive T-cell therapy is a “boutique” treatment that is too costly and too
impractical to commercialize. Our group performed a profitability analysis on a commercial-scale T-cell
manufacturing facility based in Philadelphia and found that it could in fact be profitable. Furthermore, we
pinpointed a cell separation step in the current procedure that was not optimal. We modeled the
separation and determined an optimal operating protocol that would decrease the failure rate from 10% to
1%, increasing profitability in our facility by 25 million dollars.
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Professor Fabiano and Dr. Wattenbarger,

In the fall semester of 2014, you asked us to improve and scale up the T-cell manufacturing
process being used at the Hospital of the University of Pennsylvania. Although still early in its
development, adoptive T-cell therapy has shown clinical success in the treatment of acute
lymphoblastic leukemia (ALL) to such great effect that it has contributed to Science magazine
naming cancer immunotherapy the breakthrough of 2014. Despite the initial success of T-cell
therapeutics for the treatment of ALL, commercialization of the treatment has not yet occurred.
Due to the lack of precedent for T-cell therapeutics, two challenges arise. The first is that there is
no basis for assessing the profitability of the scaled up process. The second is that tailored
equipment has not yet been designed for T-cell manufacture, leaving manufacturers using
suboptimal equipment and protocols. This past semester, our group attempted to tackle both
problems.

First, we performed a market and competitive analysis to determine whether building a
commercial T-cell manufacturing plant for the production of ALL therapeutics would be
profitable. Our calculations indicated that a commercial T-cell process was indeed profitable. As
a second component of our project, we modeled a cell separator and developed a protocol for
optimal separation of red blood cells from white blood cells. We predict that our proposed
modification will improve the overall success rate of the procedure and accordingly, the
profitability as well.

Sincerely

Amit Pujari

Chi-Wei Man
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Chapter 1: Abstract
1.0: Abstract
Adoptive T-cell therapy is a recent medical development that has shown clinical success
in treating relapsed acute lymphoblastic leukemia (ALL), a common form of cancer with a poor
prognosis. Ironically, the treatment’s greatest advantage is at the same time deterring large
pharmaceutical companies from commercializing it. Adoptive T-cell therapy is successful in
treating ALL largely because it takes a patient’s own cells and engineers them to fight the
cancer. While the autologous nature of the treatment helps to incorporate the engineered T-cells
into the patient’s body, it also makes each treatment patient-specific. This does not fit into the
paradigm of large pharmaceutical companies, who want “off the shelf” drugs. Critics claim that
adoptive T-cell therapy is a “boutique” treatment that is too costly and too impractical to
commercialize. Our group performed a profitability analysis on a commercial-scale T-cell
manufacturing facility based in Philadelphia and found that it could in fact be profitable.
Furthermore, we pinpointed a cell separation step in the current procedure that was not optimal.
We modeled the separation and determined an optimal operating protocol that would decrease
the failure rate from 10% to 1%, increasing profitability in our facility by 25 million dollars.
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Chapter 2: Introduction
2.0: Background
T-cells are a type of white blood cell (leukocyte) that serve as the initiators of the
adaptive immune response. They possess a crucial T-cell receptor that recognizes exogenous
cells. Note that exogenous can refer to either an invading pathogen or a tumor cell, which is a
mutated version of an endogenous cell. To become activated and initiate the immune response,
the T-cell must recognize an antigen, which is a small identifying protein, bound to major
histocompatibility complex (MHC). MHC “processes” the antigen such that it can be recognized
by the T-cell. See figure 2.1 for a schematic of T-cell activation. Once activated, T-cells trigger a
cascade of events. Most notably, they expand and release cytokines, which are small signaling
proteins that stimulate other immune cells. This causes immune cells to target and destroy cells
presenting the antigen of interest. A disease such as acute lymphoblastic leukemia (ALL) is
lethal because tumor cells down-regulate MHC. Without MHC, T-cells cannot recognize
antigens and become activated. Thus, the adaptive immune response is effectively shut down.

Tumor cell

Figure 2.1: T-cell activation.1 The
T-cell receptor on the cytotoxic Tcell recognizes the antigen/MHC
complex represented by the blue
triangles and green rectangles. This
initiates the adaptive immune
response.
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A research team at the University of Pennsylvania has found a way to engineer T-cells to
bypass the tumor escape mechanism of leukemic tumor cells. This method, dubbed chimeric
antigen receptor therapy involves genetically engineering T-cells to replace their natural receptor
binding domain with an antibody binding domain, which allows the T-cell to recognize antigens
without MHC. A natural T-cell receptor comprises three domains: a receptor domain which
recognizes antigen and MHC complexes, an intermembrane domain that anchors the receptor to
the T-cell, and a signaling domain which releases molecules that signal for the destruction of
pathogenic cells. Figure 2.2A shows this modified chimeric antigen receptor (CAR). As the
figure shows, only the binding domain of the receptor is replaced. The T-cell signaling domain is
left intact, allowing for the regular immune response signaling cascade to occur once the CAR
cell has been activated. CAR T-cells are able to recognize antigens bound to the surface of tumor
cells without the need for MHC, as figure 2.2B and figure 2.2C show.

A

B

C

Figure 2.2: A) Diagram of chimeric antigen receptor (CAR). 2 The signaling domain, labeled as “ligand
binding domain” is now an antibody binding domain, which allows it to recognize antigens without requiring
the presence of MHC. The transmembrane and signaling domains remain intact. B) Activation of an
unmodified T-cell. This requires recognition of an antigen bound to MHC. C) Activation of a chimeric antigen
receptor T-cell.3 This type of cell can recognize antigens on tumor cells without requiring the antigen to be
bound to MHC.
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Initial results of CAR therapy have been successful. In a clinical trial published October
of 2014 in the New England Journal of Medicine, Dr. Carl June and his research team showed
that their CAR therapy was extremely effective in treating patients with ALL. Out of the 30
patients enrolled in the study, 27 of them experienced complete remission, a 90% success rate.4
This result is made even more impressive because most of the patients had already undergone
chemotherapy and stem cell infusions, both of which had failed. Thus, adoptive T-cell therapy is
a new form of medicine that is likely to entirely disrupt the cancer therapy market.
T-cell manufacturing is the process by which a patient’s endogenous T-cells are
converted into therapeutics. As the name suggests, adoptive T-cell therapy involves removing a
patient’s T-cells, culturing and genetically modifying them ex vivo, then infusing them back into
the patient. Figure 2.3 illustrates the general process in more detail. In the first step of apheresis,
the blood is removed from the patient, and the white blood cells, containing the T-cells, are
separated from the rest of the blood. Next, the cells are cultured ex vivo and expanded. This step
involves using antigen presenting beads to stimulate growth and division of T-cells. They are
then genetically modified using synthetic biology to convert T-cells into CAR T-cells. In the
final treatment step of reinfusion, cells are washed and then infused back into the patient.
Following treatment, the patient is monitored in a medical facility for signs of improvement or
decline. The major advantage of the process is that it is autologous, meaning that the adopted Tcells are derived from the patient’s own cells, which reduces chances of immunogenicity
(patient’s immune cells rejecting the introduced therapeutic). Currently, the Clinical Cell and
Vaccine Production Facility (CCVPF) at the Hospital of the University of Pennsylvania is one of
only several facilities engaged in the manufacture of T-cell therapeutics. Their therapeutic is
called CTL019.

10

2
3

4
1

Figure 2.3: Schematic of T-cell manufacture.5 Step 1: whole blood, containing T-cells is removed from the body, and the T-cells
are purified. Step 2: T-cells are grown and expanded ex vivo, Step 3: T-cells are genetically modified to better fight a targeted
disease. Step 4: Modified T-cells are reinfused back into the patient’s body.
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The goal of our project was to design a scaled up commercial facility for the manufacture
of T-cell therapeutics to treat ALL. As part of the design, we assessed whether or not the
commercial facility was profitable and worth pursuing given the available market. In addition,
we also modeled a cell separation step to increase the purity of target T-cells in the product
stream. Our method of showing increased purity was calculating the difference between average
residence times of target and waste cells. We propose that our purer T-cell products will increase
the profitability of our plant.
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2.1: Project charter and scope
Project Name

Adoptive T-cell manufacture for treatment of acute lymphoblastic
leukemia

Project

Dr. Miriam Wattenbarger, UPenn; Dr. Bruce Levine, Hospital of the

Champions

University of Pennsylvania

Project Leaders

Amit Pujari, Chi-Wei Man, Jinsang Park

Specific Goals

Design a commercial-scale T-cell manufacturing facility for the
production of CTL019 to treat acute lymphoblastic leukemia

Project Scope

In-Scope


Market and competitive analysis



Demographic analysis of facility location



cGMP compliance



Commercial facility equipment specifications



Cell separator operating procedure



Profitability analysis

Out-of-Scope

Deliverables

Timeline



Packaging and distribution of T-cell therapeutics



Clinical trials for FDA approval of therapy



Molecular biology of T-cell manufacturing process



Cell separation device design



Modeling of cell release profiles for various operating conditions



Profitability analysis of commercial manufacturing facility

Complete report of plant specifications and profitability before April 14,
2015
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2.2: Innovation map
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Chapter 3: Concept stage
3.0: Market and competitive analysis
The goal of this therapy is to produce a T-cell modification in patients with severe acute
lymphoblastic leukemia (ALL). While the therapy has the potential to treat other conditions
including HIV/AIDS, the scope of this project will only include the ALL process. While the total
number of patients with ALL in the US is approximately 66,000, there are an estimated 6250
new ALL patients and 1450 deaths from ALL each year. ALL disproportionately affects younger
populations; it is the most common form of cancer found in patients aged 0 to 14 (American
Cancer Society, 2014). This form of leukemia is characterized by the presence of too many
lymphoblasts in the bone marrow and can quickly spread to other parts of the body due to the
distribution channels within the immune system. While life expectancy has been slightly
increasing, few of the currently used treatments have consistently shown complete remission of
the disease.
According to the Cancer Treatment Centers of America, the current treatment options
available to ALL patients include chemotherapy, stem cell transplant, radiation therapy, and
immunotherapy. Many of these treatments are commonly used options for other forms of cancer
as well. Approximately 80% of ALL patients who undergo chemotherapy will go into remission,
although the cancer eventually returns in some cases. While many of the treatments available are
effective, even if temporarily, they often come with lasting side effects. Most recognizable of
these would be the associated hair loss due to radiation and chemotherapies, drop in blood cell
counts, mouth sores and ulcers, and general tiredness. Of the available treatments, our Adoptive
T-cell therapy (immunotherapy) is the first to show results of complete remission in almost all
patients, and without any severe, lasting side effects. Currently in Phase I and II clinical trials,
the adoptive T-cell therapy is being considered for use in patients who have exhausted the other
potential treatments. If approved, the adoptive T-cell therapy could be considered for treatment
of all ALL patients to significantly increase the likelihood of complete remission.
Creating a facility like the cGMP site where the clinical trials are currently being
conducted is a significant barrier to entry. Due to the strict guidelines required for an approved
Good Manufacturing Practice (GMP), building such a facility can be extremely expensive and
16

laborious. In addition to the high construction costs, the facility also requires additional costs and
labor to continue operating. There are however several such facilities in existence including ones
in Boston, Seattle, Ireland, New York, Cincinnati, Utah, California and Miami. While these
facilities have the potential capability to produce a similar therapy, most are not currently
producing similar therapies. Table 3.1 shows many of the currently operating cGMP facilities as
well as some available information regarding size and history about each of them.
Table 3.1: Potential competing cGMP facilities in existence.6,7,8,9,10,11,12,13,14,15,16,17

Name

Location

Size

Founded

Harvard Cancer

Cambridge, MA

-

1996

Seattle, WA

-

1975

Center
Fred Hutchinson
Cancer Research
Center
REMEDI

Ireland

250 m2

-

Waisman

Madison, WI

7 rooms

2001

Buffalo, NY

2574 ft2, 7 rooms

2008

12,000 ft2

1998

-

-

Biomanufacturing
Roswell Park
Cancer Institute
Baylor University

Waco, TX

Hoxworth Blood

Cincinnati, OH

Center
University of Utah

Salt Lake City, UT

9,222 ft2, 7 rooms

1996

CESCA

New York City, NY

-

-

Laboratories
City of Hope

Philadelphia, PA

10,000 ft2

-

Case Western

Cleveland, OH

10,000 ft2

-

University
Batavia Bioservices

Netherlands

-

-

University of Miami

Miami, FL

-

2008
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Seattle Children’s, a hospital system located in Seattle, Washington is one of the few
direct competitors to the process. The center opened its Program for Cell and Gene Therapy in
2014 and is already conducting Phase I and II clinical trials for their own adoptive t-cell therapy
for leukemia, and specifically ALL, as it is the most common form of cancer diagnosed in
children. The Memorial Sloan Kettering Cancer Center, initially founded in 2003 in New York
City, NY, has also begun clinical trials on an adoptive t-cell therapy for ALL that functions
similarly to the University of Pennsylvania process. As the only potential competitor located
within the region surrounding Philadelphia, Sloan Kettering would pose the only challenge to
control of the market share. The capacity and sales projections will be further discussed in the
economic analysis.
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3.1: Market share analysis
When determining the share of the market that can be obtained, the target customer base
was limited to the areas surrounding the intended facility location. While blood samples taken
from the patient are typically cryo-preserved and shipped via an airplane, transportation costs can
be severely reduced if the clinic where apheresis occurs is located within four hours driving
distance of the processing facility. In these situations, the samples can be immediately
transported as fresh samples, saving both time and money. Using Philadelphia, PA as the facility
location, figure 3.1 shows a graphical representation of expected market region:

Figure 3.1: Area reachable by car within four hours from Philadelphia, assuming an average 60 mph speed.

Of the 66,000 patients with ALL in the country, accounting for the relative size and
population density of the intended region puts approximately 9479 ALL patients currently living
within the area4. 898 new ALL patients are discovered within this region every year, increasing
the potential market size. The Memorial Sloan Kettering Cancer Center is located within the
desired region and would thus serve as the main potential competitor for the product.
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According to a study by H. G. Grabowski and J.M. Vernon5, the effective patent life of
new pharmaceutical drugs and therapies is close to twelve years (2000). With this patent life, an
operating company could expect to maintain high profits for these twelve years before the
introduction of generics to the market would drastically reduce the achievable revenue due to
competition. Over the course of twelve years, approximately 20,255 ALL patients will be
available for treatment. Due to the high expected price of the treatment, it is likely that many
individuals with weak or no health insurance coverage will not be able to opt for the treatment.
According to a Kaiser Family Foundation report, the number of Americans without health
insurance was as high as 50 million in 2010. While that number may have decreased by 2015,
this statistic still significantly affects the potential market size as the poor are disproportionately
likely to miss diagnosing ALL in its early stages when less drastic treatments would be effective.

3.2: Customer requirements
Acute lymphoblastic leukemia affects 66,000 individuals in the US and that number
grows by 6250 each year. Scaling these statistics down to account only for the region located
within a reasonable driving distance of the facility, the region would contain 9479 patients with
898 new patients each year. The product must match fitness-to-standard because the quality of
the therapy cannot be compromised as the product is directly injected into the patients. The
cGMP facility requirements are in place to ensure that all products are safe for biological
exposure.

3.3: cGMP facilities and manufacturing
The US is generally stricter than most other countries when it comes to industrial
regulations. With the increasing frequency of drugs and other biological supplements being
brought to the market, it was necessary to establish a standard by which to ensure that all
substances purposely administered to patients are safe. Good manufacturing practice (GMP) was
first proposed during the 1963 GMP Regulations and Amendments to promote its effectiveness
and increased safety (Gee). With the increasing popularity and effectiveness of cell treatments
20

like the adoptive T-cell therapy and stem cell therapy, the medical community recognized the
need for a standard policy regarding the handling of the manufacturing process for these
treatments.
These GMP facilities were carefully planned to provide an efficient process flow. It is
generally accepted that stand-alone facilities are advantageous to GMP sections of existing
facilities, because the GMP practices can be set in effect for the entire building, with no
confusion as to its implementation. Facilities usually function best with a unidirectional travel
pattern along a central passage. As seen in figure 3.2, the doors on the left are likely the
individual cell processing rooms, which only handle one patient at a time. The door on the right
is likely a central equipment storage room for common use by workers from all of the cell
processing rooms.

Figure 3.2: A typical cGMP main corridor layout.18
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HEPA air filtration is required in all cGMP facilities, as seen in subpart C of table 3.2.
HEPA filtration creates a higher pressure within the facility to prevent any contaminants in the
air from incidentally entering the rooms. In addition to this system, there are a number of
precautions in place to ensure sanitary conditions. Personal protective equipment (PPE),
specialized windows for quick transfer of any materials or waste, as well as frequent cleaning are
just a few of these. When designing the layout of a cGMP facility, architects seek to create two
distinct circulations, one for materials/services and one for workers. The materials circulation is
separated into clean and dirty paths to distinguish between the product and the waste,
respectively. Smaller cell processing rooms are used to isolate the process pathway for each
individual patient. The cells from any given patient remain in the same room throughout the
entire process and equipment are wheeled into the room from the central storage room.
The specific policies for cGMP facilities are outline into various subparts, as seen in table
3.2. Each subpart covers a specific aspect of regulation required to pass cGMP guidelines. The
AABB Committee on Inspection and Accreditation was established in 1960 to help certain
regulated facilities meet local, state and federal requirements. It later expanded to also govern the
control of cellular therapy product services in the 1990’s. Almost all blood banks and transfusion
centers are now members of AABB and thus comply with the requirements of the Clinical
Laboratory Improvement Amendments.
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Table 3.2: Expected components of a GMP facility include the following subparts

Subpart

Explanation

A

Must continuously update standards to match the current practices

B

Must contain a quality control (QC) unit with the authority to approve/reject
components, review production records, and approve/reject all procedures or
specifications
Personnel must be trained, educated and provided the proper personal hygiene and
health habits

C

Building and facilities must contain proper size and layouts, a ventilation (HVAC)
and air filtration system, plumbing, washing and toilet facilities, and maintenance
and cleaning designed to prevent contamination

D

All equipment must be designed with the proper construction, cleaning and
maintenance standards to prevent contamination, mix-ups and errors

E

All components, containers and closures must contain written procedures describing
proper handling, receipt and storage, testing and approval

F

Production controls must contain written procedures for the charging of
components, identifying equipment, sampling, and contamination control
Any deviations from these should incur investigation with a good root cause
analysis and actions to correct the situation

G

All packaging and labeling must contain written details for examination, operation,
inspection confirmation and expiration dates

H

All warehouse storage must be quarantined and appropriately stored for conditions
appropriate to the product
The distribution should have proper inventory documentation and tracking

I

All laboratories should confirm to appropriate specifications and assure the strength,
purity and stability of all samples are ideal

J

Records and reports should be stored and available for inspection on request
including any logs, files or records

K

Drug products should be quality confirmed based on controls and requirements
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3.4: Product concepts
The options available to current ALL patients include a combination of different
techniques depending on the severity and responsiveness of the particular patient. Before the
development of immunotherapy, the typical options consisted of chemotherapy, interferon
therapy, radiation therapy, stem cell transplantation and surgery. Stem cell treatment is usually
considered last and in combination with the other forms of therapy. Immunotherapy, such as the
adoptive T-cell treatment is unique, because it utilizes the immune system of the patient to
combat the disease. The first immunotherapy for ALL to receive FDA approval is Amgen’s
Blincyto (Bloomberg Business, 2014). This drug facilitates interaction between CD3 proteins on
t-cells and the CD19 proteins characteristic of this cancer. Unlike the adoptive T-cell therapy,
this process does not require modification of the T-cells, but is resultantly less effective. A
standard course of treatment for Blincyto costs $178,000 for two four-week treatments. While
Blincyto is less invasive and can be administered without a turnaround time, clinical trials
showed complete remission in only 32 percent of patients.
A common chemotherapeutic drug for ALL is asparaginase. Costs of a full course of
treatment can soar upwards of $57,893 for a 30 week treatment and up to around $113,558 under
certain circumstances (Tong, et al.)19. While this treatment course, when administered with an
early diagnosis can be effective in some cases, the process takes many months to complete and
results in side effects commonly associated with chemotherapy including hair loss and
compromised immune systems. The outlook for patients with ALL varies based on a number of
factors, but younger patients do tend to have a significantly longer life expectancy and chance of
remission. With early diagnosis, children with ALL have a roughly 80% chance of living longer
than five years. Approximately 40% of adults diagnosed with ALL will live longer than five
years.
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3.5: Superior product concept
The adoptive T-cell therapy surpasses the alternative treatments in multiple aspects. Early
clinical trials in ALL patients who had exhausted all other options showed a greater than 57
percent rate of complete remission (NY Times, 2014). Tumors and other significant signs of the
cancer typically disappear within two weeks of the treatment. While the T-cells are attacking the
tumor, the body usually exhibits cytokine release syndrome that manifests itself in fever, aches,
drops in blood pressure and trouble breathing. The survival rate for this study was even greater.
The adoptive T-cell therapy is also potentially much cheaper than alternative options. Without
the need for large reactors or equipment to produce a drug on an industrial scale, the cost of
production for the therapy drops well below the price of the main competitors. Administration of
the therapy is also easily facilitated; adoptive T-cell therapy requires a single injection, close to
two weeks after the initial blood collection. Patients with severe ALL often do not have long life
expectancies and the adoptive T-cell therapy would ensure that more patients survive long
enough to receive proper treatment.
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Chapter 4: Process flow and material balance
4.0 Process flow diagram
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4.1: Overall material balance for a treatment
PFD-01
Component

Unit

Initial
Product

Additional
Input

Waste
Output

Final
Product

mL

450

11040.02

11390.02

100

Red Blood Cell

cells/mL

4.44×108

0

1.76×107

1.90×105

White Blood Cell

cells/mL

3.33×107

0

1.70×106

5.90×108

Granulocytes

cells/mL

4.02×106

0

1.56×105

4.10×105

Monocytes

cells/mL

6.98×106

0

2.70×105

7.39×105

T-cell

cells/mL

2.22×107

0

1.26×106

5.89×108

Suppressor T-cell

cells/mL

1.11×105

0

4.41×103

1.69

Platelets

cells/mL

1.04×109

0

3.98×107

1.84×108

Plasma

mL

244.35

0

244.29

0.06

CD4 Microbeads

mL

0

0.02

0.02

0

CD3/28 Dynabeads

mL

0

0.84

0.84

0

Buffer

mL

0

1100

1085

15

Cell Culture Media

mL

0

9940

9805

135

Glucose

g/mL

0

1.00×10-3

1.24×10-4

1.12×10-4

Glutamine

g/mL

0

2.92×10-4

0

0

Volume
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4.2: Stream summary for PFD 01
Stream Name

S-C1

S-C2

S-C3

S-01

S-02

Source

P-C1

P-C2

P-C2

P-C3

Destination

P-C2

P-C3

P-C1

P-01

P-01

Stream Properties

Unit

Temperature

°C

23

23

23

23

23

Pressure

Atm

1

1

1

1

1

Volume

mL

10000

450

9550

450

150

Red Blood Cell

cells/mL

5.20×109 4.44×108 5.42×109 4.44×108 0

White Blood Cell

cells/mL

7.50×106 3.33×107 6.29×106 3.33×107 0

Granulocytes cells/mL

9.07×105 4.02×106 7.60×105 4.02×106 0

Monocytes cells/mL

1.57×106 6.98×106 1.32×106 6.98×106 0

T-cell cells/mL

4.99×106 2.22×107 4.19×106 2.22×107 0

Suppressor T-cell cells/mL

2.51×104 1.11×105 2.10×104 1.11×105 0

Platelets

cells/mL

3.50×108 1.04×109 3.17×108 1.04×109 0

Plasma

mL

5430

244.35

5185.65

244.35

0

CD4 Microbeads

mL

0

0

0

0

0

CD3/28 Dynabeads

Beads/mL

0

0

0

0

0

Buffer

mL

0

0

0

0

150

Cell Culture Media

mL

0

0

0

0

0

Glucose g/mL

0

0

0

0

0

Glutamine g/mL

0

0

0

0

0

Component
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S-03

Stream Name
Source

S-04

S-05

P-03

P-03

P-03

Destination

S-06

S-07
P-03

P-04

P-03

Stream Properties

Unit

Temperature

°C

23

23

23

23

23

Pressure

Atm

1

1

1

1

1

Volume

mL

600

540

60

750

750

Red Blood Cell

cells/mL

3.33×108 3.67×108 3.33×107 0

2.40×106

White Blood Cell

cells/mL

2.50×107 1.85×107 8.27×107 0

3.44×106

Granulocytes cells/mL

3.02×106 3.17×106 1.67×106 0

6.93×104

Monocytes cells/mL

5.23×106 5.48×106 3.00×106 0

1.25×105

T-cell cells/mL

1.66×107 9.80×106 7.80×107 0

3.24×106

Suppressor T-cell cells/mL

8.33×104 9.25×104 1.30×103 0

2.71×101

Platelets

cells/mL

7.83×108 6.48×108 2.00×109 0

1.31×108

Plasma

mL

244.35

219.92

24.44

0

18.31

CD4 Microbeads

mL

0

0

0

0

0

CD3/28 Dynabeads

beads/mL

0

0

0

0

0

Buffer

mL

150

135

15

750

693

Cell Culture Media

mL

0

0

0

0

0

Glucose g/mL

0

0

0

0

0

Glutamine g/mL

0

0

0

0

0

Component
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Stream Name

S-08

S-09

Source

P-03

Destination

P-04

P-04

S-10

S-11

P-04

P-04

S-12

P-05

P-05

Stream Properties

Unit

Temperature

°C

23

23

23

23

23

Pressure

Atm

1

1

1

1

1

Volume

mL

60

200

200

60

0.89

Red Blood Cell

cells/mL

3.33×106 0

5.00×104 3.17×106 0

White Blood Cell

cells/mL

3.97×107 0

5.95×105 3.77×107 0

Granulocytes cells/mL

8.00×105 0

1.20×104 7.60×105 0

Monocytes cells/mL

1.44×106 0

2.16×104 1.37×106 0

T-cell cells/mL

3.74×107 0

5.62×106 3.56×107 0

Suppressor T-cell cells/mL

3.13×102 0

9.29×101 3.13

Platelets

cells/mL

3.59×108 0

5.39×106 3.23×108 0

Plasma

mL

6.12

0

0.31

5.82

0

CD4 Microbeads

mL

0

0.07

0

0.07

0

CD3/28 Dynabeads

Beads/mL

0

0

0

0

4.00×107

Buffer

mL

57

200

198

59

0

Cell Culture Media

mL

0

0

0

0

0

Glucose g/mL

0

0

0

0

0

Glutamine g/mL

0

0

0

0

0

Component
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0

S-13

Stream Name

S-14

S-15

P-05

Source
Destination

S-16

S-17

P-06

P-07

P-05

P-06

P-06

P-07

Stream Properties

Unit

Temperature

°C

23

23

23

23

23

Pressure

Atm

1

1

1

1

1

1000

1,060.89

8940

10000.89

Component
Volume

mL

0.89

Red Blood Cell

cells/mL

0

1.79×105

0

1.90×104

0

White Blood Cell

cells/mL

0

8.13×106

0

6.55×106

0

Granulocytes cells/mL

0

4.30×104

0

4.56×103

0

Monocytes cells/mL

0

7.74×104

0

8.21×103

0

T-cell cells/mL

0

8.01×106

0

6.54×106

0

Suppressor T-cell cells/mL

0

1.77×10-1

0

1.88×10-2

0

Platelets

cells/mL

0

1.93×107

0

2.05×106

0

Plasma

mL

0

5.82

0

5.82

0

CD4 Microbeads

mL

0

0

0

0

0

CD3/28 Dynabeads

beads/mL

0

3.77×104

0

4.00×103

4.00×103

Buffer

mL

0

59

0

59

0

Cell Culture Media

mL

1000

1000

8940

9940

0

Glucose g/mL

1.00×10-3

8.58×10-4

1.00×10-3

8.58×10-4

0

Glutamine g/mL

2.92×10-4

0

2.92×10-4
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0

Stream Name

S-18

S-19

S-20

Source

P-07

P-08

P-08

Destination

P-08

P-09

Stream Properties

Unit

Temperature

°C

23

23

23

Pressure

Atm

1

1

1

Volume

mL

10000

9900

100

Red Blood Cell

cells/mL

1.90×104

1.73×104

1.90×105

White Blood Cell

cells/mL

6.55×106

6.62×105

5.90×108

Granulocytes cells/mL

4.56×103

4.61×102

4.10×105

Monocytes cells/mL

8.21×103

8.29×102

7.39×105

T-cell cells/mL

6.54×106

6.61×105

5.89×105

Suppressor T-cell cells/mL

1.88×10-2

1.90×10-3

1.69

Platelets

cells/mL

2.05×106

2.07×105

1.84×108

Plasma

mL

5.82

5.76

0.06

CD4 Microbeads

mL

0

0

0

CD3/28 Dynabeads

beads

0

0

0

Buffer

mL

59

44

15

Cell Culture Media

mL

9940

9805

135

1.41×10-4

1.44×10-4

1.67×10-4

0

0

0

Glucose g/mL
Glutamine g/mL
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Chapter 5: Process description
5.0: Blood collection in clinics (P-C2)
To collect T-cells, peripheral blood mononuclear (PBMC) concentrates are collected
from an acute lymphoblastic leukemia patient using a blood cell separator (COBE® Spectra
Apheresis System). A blood from a patient is continuously run through the cell separator
machine and returned to the body until enough T-cell is collected for analysis. A total volume of
8~12 L of whole blood is processed, and about 450mL of blood sample with the quantity of
white blood cells between 5~20×109 cells is desired. The red blood cells, platelets, and the rest of
the white blood cells are returned to the body. A collected blood is transferred either fresh (if it
can be delivered within 4 hours) or frozen to adoptive t-cell therapy production facility (Clinical
Cell and Vaccine Production Facility at Hospital of the University of Pennsylvania).

5.1: Elutriation (P-02)
To separate red blood cells and white blood cells, the PBMC concentrate collection is
processed with counter-flow elutriation instrument (Elutra® Cell Separating System, Terumo
BCT) with a user-defined profile. A 450mL of patient’s PBMC concentrate will be mixed with
elutriation buffer of 150 mL and go through counter-flow elutriation at 2400 RPMs and the
media flow rate is maintained at 20mL/min for fraction 1 (high RBC concentration) and
60mL/min for fraction 2 (high WBC concentration). The fraction 2 is collected and used for the
next step. The fraction 1 and the cells remaining in the chamber are collected with the rotor off
and disposed.

5.2: Cell washing (P-03)
To wash cells for higher white blood cell purity, cells collected after the elutriation is
washed out in a collection buffer in an automated cell-washing device (Cell Saver® 5+
Autologous Blood Recovery System). A centrifuge bowl size of 125ml is used with 750mL of a
buffer solution at 4350 RPMs and media flow rate of 500mL/min.
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5.3: Suppressor T-cell removal (P-04)
To remove regulatory (or suppressor) T-cell (CD4+), a magnetic extraction was
performed using electromechenical cell separating device. (CliniMACS®). A removal of
suppressor T-cell is desired because tumor cells in the body can block immune system upon
recognizing suppressor t-cell, inhibiting t-cell immunotherapy to work efficiently. The washed
cells from Cell Saver are magnetically labeled using conjugated particle to anit-CD4 (CD4
Microbeads, Miltenyi Biotec). A sterile, disposable tubing set is used to connect the bag
containing the labeled cells to the device. The cell sample in a separation column under magnetic
field separates out the labeled cells, undergoes several washing steps, and elutes the purified
target cells (CD3/CD28).

5.4: Cell culture in gas permeable bag (P-05)
To grow T-cells, purified target cells sample is cultured in a nutrient media with an
addition of antibody-coated magnetic beads (Dynabeads® Human T-Activator CD3/CD28) and
gene vectors for the stimulation of cell division and growth. The mixture of cells, magnetic
beads, gene vectors, and growth media are added to a 1000mL gas-permeable plastic bag
(MACS® GMP Cell Culture Bag). The cells are grown in a closed system to minimize the risk of
contamination. The cell suture is maintained in a gas permeable bag for 3-5 days.

5.5: Cell expansion in bioreactor (P-06)
To expand T-cells further, the cell culture is transferred to a bioreactor (WAVE
Bioreactor™ 2/10) during the log-phase cell growth. Cultures are maintained in a bioreactor for
4-6 days. A total 4000mL of cell culturing media (CTS™ OpTmizer™ T Cell Expansion SFM)
is fed over the period.
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5.6: Dynabead removal (P-07)
To remove the magnetic dynabeads used to promote cell growth, a magnetic cell
separator (MaxSEP® System) is used after the cell expansion and before the cell harvest.

5.7: Cell harvest (P-08)
To collect the modified T-cells and remove other contaminants, an automated cellwashing device (Cell Saver® 5+ Autologous Blood Recovery System) is used. The cell culture
sample was processed at 4350RPMs at the flow rate of 1000mL/min for multiple washing cycles.
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Chapter 6: Modeling
6.0: Motivation
From talking to CCVP staff, we identified a critical step of the process that needed
improvement. This was the elutriation that involves the Terumo Elutra®. The purpose of this
step is to separate leukocytes (white blood cells) from erythrocytes (red blood cells). The
leukocytes, which contain the desired T-cells must be rid of erythrocytes. If allowed to remain in
the cell mixture, cell processing protocols in following steps will cause red blood cells to lyse,
releasing their toxic contents into the overall mixture. This kills the T-cells of interest, either
lengthening the following cell culture steps or causing the operation to fail outright. Accordingly,
this step of the procedure is crucial. Though elutriation typically has a high success rate, the
separation is less effective for blood samples that have low leukocyte counts to start with, which
is not uncommon considering the fact that these patients are immune-compromised to begin
with.
In this section, we develop a model for the separation of erythrocytes from leukocytes.
Currently, the CCVP is using the same protocol for each different patient, which leads to failure
in patients with low leukocyte counts. Based on second-hand sources, we predict the current
failure rate to be 10%. By modeling the elutriation process, we hope to gain insight on how
various parameters affect the difference in average residence times between leukocytes and
erythrocytes. Using the model, we will make a recommendation on an optimized operating
protocol for the removal of erythrocytes from the cell mixture. We predict that optimizing the
protocol will result in a reduction of the failure rate from 10% to 1%. This is significant not only
in its economic implications. A successful separation could mean the difference between life and
death for a suffering patient.

38

6.1: Theoretical background
Counterflow centrifugal elutriation (CCE) is the technique that the Terumo Elutra® uses
for its separation, and it is the technique which we base our model. CCE separates particles based
on both size and density. Figure 6.1A schematically illustrates CCE. Blood cells are pumped
through the chamber from outside to inside while the chamber spins around. This applies two
opposing forces on particles within the fluid, a drag force that pushes particles through the
chamber and a centrifugal force that opposes movement of the particle through the chamber (see
Figure 6.1B).

A

B
Fd

Q

Fc

Figure 6. 4: A) Schematic for counterflow centrifugal elutriation. B) Force balance on a particle inside the chamber.

Theoretical estimates for the forces on the particle were performed by Morijiri et al.1 The
centrifugal force, Fc is expressed by Equation 1.
𝐹𝑐 =

𝜋 3
𝐷 (𝜌 − 𝜌𝑓 )𝑟𝜔2
6 𝑝 𝑝

Where Fc = centrifugal force
Dp = particle diameter
ρp = particle density
ρf = fluid density
r = distance from axis of rotation
ω = angular velocity
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Equation 1

The fluid drag force, Fd is approximately given by Equation 2 for small Reynolds number
(Re < 1).
𝐹𝑑 = 3𝜋𝜇𝐷𝑝 𝑈{𝑟} = 3𝜋𝜇𝐷𝑝 (𝑈𝑓 {𝑟} − 𝑈𝑝 {𝑟})

Equation 2

Where Fd = fluid drag force
μ = fluid viscosity
U{r} = relative particle flow velocity at r
Uf{r} = average flow velocity at r
Up{r} = particle flow velocity at r
𝑈𝑓 {𝑟} =

𝑄
𝑆{𝑟}

Equation 3

Where Q = volumetric flow rate through chamber
S{r} = cross-sectional area of chamber at r

6.2: Determination of cell dimensions
From literature, we found physical dimensions for leukocytes and erythrocytes.1 These
are given in table 6.1. Leukocytes are spherical, so their dimensions are rather straightforward
for the purposes of the model; however, erythrocytes are disk-shaped. Thus, we need to reduce
these cells to a sphere and calculate an effective diameter.
Table 6.1: Dimensions of erythrocytes and leukocytes

Cell Type
Erythrocytes
Leukocytes

Density (g/cm3)
1.10
1.07

Shape
Disk
Sphere
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Diameter (μm)
7
12

Thickness (μm)
2
NA

To calculate an average effective diameter for erythrocytes, we used a method described
by Li et al. to calculate effective diameter of non-spherical particles in a packed bed reactor.2
Sphericity of erythrocytes was first calculated. This is detailed by Equation 4. For the case of
disk-shaped erythrocytes with dimensions detailed by table 6.1, the sphericity was calculated as
0.723. See the sample calculations section for a more details.
𝜑=

𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑠𝑝ℎ𝑒𝑟𝑒 𝑜𝑓 𝑒𝑞𝑢𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑡𝑜 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒

Equation 4

The Sauter mean diameter (dsd) is also required to calculate the effective diameter. This is
defined by Equation 5. For erythrocytes, the value was calculated as 3.82 μm. Finally, the
effective diameter is defined by Equation 6, and this is simply the product of the Sauter mean
diameter and sphericity. For erythrocytes, the effective diameter was calculated to be 2.76 μm.
See Appendix B for detailed calculations. Table 6.2 gives the new cell dimensions that will be
used in the model.
𝑑𝑠𝑑 =

6𝑉𝑝
𝐴𝑝

Equation 5

Where dsd = Sauter mean diameter
Vp = volume of particle
Ap = surface area of particle
𝑑𝑒𝑓𝑓 = 𝜑𝑑𝑠𝑑

Equation 6

Where deff = effective diameter

Table 6.2: Modified cell dimensions table

Cell Type

Effective Diameter (μm)

Density (kg/m3)

Mass (kg)

Erythrocytes

2.76

1100

1.21*10-14

Leukocytes

12

1070

9.68*10-13
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6.3: Solving for particle movement in the chamber
To solve for particle movement in the chamber versus time, we performed a force
balance on a single particle in the chamber. This is shown by Equation 7. Algebraic
rearrangement of Equation 7, combined with the identities of Equation 8 and Equation 9 result in
an ordinary differential equation (Equation 10).
𝐹𝑛𝑒𝑡 = 𝐹𝑐 − 𝐹𝑑 = 𝑚𝑝 𝑎𝑝
𝑈𝑝 {𝑟} =

𝑎𝑝 =

𝑚𝑝

𝑑𝑟
𝑑𝑡

𝑑2𝑟
𝑑𝑡 2

𝑑2𝑟
𝑑𝑟 𝜋 3 2
− 3𝜋𝜇𝐷𝑝
− 𝐷 𝜔 (𝜌𝑝 − 𝜌𝑓 )𝑟 + 3𝜋𝜇𝐷𝑝 𝑈𝑓 {𝑟} = 0
2
𝑑𝑡
𝑑𝑡 6 𝑝

Figure 6.5: Diagram of cell separator chamber dimensions
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Equation 7

Equation 8

Equation 9

Equation 10

6.4: Solving for residence time in a tube
Because Uf{r} is a function of radius in the above geometry, we decided to simplify the
problem and solve for the average residence time in a tube geometry. By setting the separation
chamber as a tube, the average fluid flow velocity becomes a constant. To solve for Uf in this
specific geometry, this is the flow rate divided by the cross-sectional area of the tube.

Figure 6.6: Diagram of tube cell CCE

With Uf as a constant, the governing equation (Equation 15) becomes a linear ordinary
differential equation. Constants were lumped, and Equation 15 was shown in the simplified form
shown in Equation 16.
𝑑2 𝑟
𝑑𝑟
− 𝐴 + 𝐵𝑟 + 𝐶 = 0
2
𝑑𝑡
𝑑𝑡
Where A =

3𝜋𝜇𝐷𝑝
𝑚𝑝
𝜋 3
𝐷𝑝 (𝜌𝑝 −𝜌𝑓 )𝜔2

B=6
C=

𝑚𝑝

3𝜋𝜇𝐷𝑝 𝑈𝑓
𝑚𝑝
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Equation 16

To solve for the residence time, Equation 16 was solved using the ODE45 function in
Matlab (see Appendix C). Some standard operating parameters for the elutriation were then
defined from comparable values from literature. These standard operating parameters are shown
in table 6.3. The elutriation buffer fluid was assumed to have the same properties as those of
water. Also, the chamber volume was set to a standard value of 4 mL,3 the rotation frequency
was set to 2400 rotations per minute, and the fluid volumetric flow rate was set as 100 mL/min.4
Initial particle position was set at Ri, and initial particle velocity was set as zero.
Table 6.3: Standard operating parameters for counterflow centrifugal elutriation

Parameter
μ

Value
6.53*10-4

ρf

1000

ω

251

D
R
Ro
Ri
Q

0.00714
0.152
0.102
0.202
-1.67*10-6

Uf

-4.18*10-2

Units
𝑠
𝑁 2
𝑚
𝑘𝑔
𝑚3
𝑟𝑎𝑑
𝑠
m
m
m
m
𝑚3
𝑠
𝑚
𝑠

Plugging the properties of erythrocytes from table 6.2 and the defined standard operating
parameters into Matlab resulted in the graphs shown in figure 6.4 and figure 6.5. From figure
6.4, the average residence time is 2.4 seconds. Figure 6.5 shows that the terminal velocity is
reached very quickly at which point the decrease in centrifugal force slowly decreases. Figure
6.6 and figure 6.7 show comparable graphs for leukocytes at standard operating conditions.
Figure 6.6 shows that the residence time is 3.0 seconds, about half a second more than that of
erythrocytes. This tells us that the release of erythrocytes and leukocytes likely overlap,
suggesting poor separation. Figure 6.7 shows that leukocytes experience a greater increase in
terminal velocity due to the decrease in centrifugal force. Various parameters will now be
manipulated to maximize the difference in residence times.
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Figure 6.7: Displacement vs. time of erythrocyte at standard operating conditions
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Figure 6.8: Velocity vs. time of erythrocytes at standard operating conditions
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Figure 6.9: Displacement vs. time of leukocytes at standard operating conditions
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Figure 6.10: Velocity vs. time of leukocytes at standard operating conditions
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6.5: Effect of changing the elutriation buffer density
First, we looked at the effect of changing the elutriation buffer density on the residence
times of leukocytes and erythrocytes. Practically, this can be done by adding salts to the
elutriation buffer solution or changing temperature and pressure of the fluid. We varied fluid
density from 900 kg/m3 to 1400 kg/m3. Although the higher buffer densities are not practical
because such a high salt concentration would cause cells to shrivel, we were interested in
exploring a wide range of densities to see the effect on residence times. The Matlab solutions
indicated that as the elutriation buffer density increased, the residence times decreased. Table 6.3
shows the residence times versus elutriation buffer densities.
Interestingly, the leukocyte residence times start out higher than the erythrocyte residence
times, but at a buffer density between 1050 and 1100 kg/m3, leukocyte residence times become
lower than erythrocyte residence times. This implies that by changing the buffer fluid density, we
can change the overall order of elutriation. Also, when the elutriation buffer density was
increased above the density of the particles, the terminal velocity started decreasing in magnitude
as the particle moved through the chamber. This is due to the centrifugal force (term B in
Equation 10) reversing its magnitude once ρf - ρp reverses in magnitude. Figure 6.8 is a graph
showing the results of table 6.3.
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Table 6.4: Table showing the effect of varying elutriation buffer density on residence times

ρf (kg/m3)
900

Erythrocyte
residence times (s)
2.46

Leukocyte
residence times (s)
4.72

Difference in
residence times (s)
2.26

950

2.45

3.64

1.19

1000 (nominal)

2.43

2.98

0.55

1050

2.41

2.54

0.13

1100

2.39

2.21

0.18

1150

2.38

1.96

0.42

1200

2.36

1.76

0.6

1250

2.34

1.6

0.74

1300

2.32

1.46

0.86

1350

2.31

1.35

0.96

1400

2.29

1.25

1.04

Time (s)

Variation in elutriation buffer density
5
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Figure 6.11: Graph of elutriation buffer density versus residence time of leukocytes and
erythrocytes. The erythrocyte residence times remain relatively constant, while the leukocyte
residence times decrease as the buffer density increases. At a point between 1050 and 1100 kg/m3,
the average residence time for leukocytes drops below that of erythrocytes, suggesting that the order
of elution can be changed by changing the buffer density.
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6.6: Effect of changing the elutriation buffer viscosity
We also looked at the effect of elutriation buffer viscosity on residence time. Similar to
modifying the fluid density, this can be performed by adding solutes to the buffer. We modified
the viscosity from 2.5*10-4 to 2.05*10-3 N*s/m2. What we found was that as the buffer viscosity
increased, the leukocyte residence time decreased, while the erythrocyte residence times did not
change very much. Table 6.5 and figure 6.9 show how the residence times were affected by
changes in viscosity. The best separations occurred when buffer viscosity was the lowest.

Table 6.5: Table showing the effect of varying elutriation buffer viscosity on residence times

μ (N*s/m2)
2.50E-04

Erythrocyte
residence times (s)
2.49

Leukocyte
residence time (s)
5.13

Difference in
residence times (s)
2.64

4.50E-04

2.45

3.37

0.92

6.50E-04 (nominal)

2.43

2.98

0.55

8.50E-04

2.42

2.82

0.4

1.05E-03

2.42

2.73

0.31

1.25E-03

2.41

2.67

0.26

1.45E-03

2.41

2.63

0.22

1.65E-03

2.41

2.6

0.19

1.85E-03

2.41

2.57

0.16

2.05E-03

2.41

2.55

0.14
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Variation in elutriation buffer viscosity
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Figure 6.12: Graph of elutriation buffer viscosity versus residence time of leukocytes and erythrocytes. As the viscosity
increases, the leukocyte residence time decreases, asymptotically approaching the residence time of erythrocytes. This
suggests that the best separations occur at low fluid viscosities.
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6.7: Effect of changing the chamber rotation frequency
The chamber rotation frequency was the next parameter we looked at. We varied the
frequency from zero to 450 radians per second. The nominal frequency of 250 corresponds to the
2400 rotations per minute that is currently used at the CCVP. Table 6.6 and figure 6.10 show the
results of varying the chamber rotation frequency on the average residence times of leukocytes and
erythrocytes. As the rotation frequency increased, the difference in residence times increased
exponentially. Interestingly, without any rotation, the difference in the residence times is zero, which
illustrates the importance of the rotation on separation of particles.

Table 6.6: Table showing the effect of varying chamber rotation frequency on residence times

ω (s-1)
0

Erythrocyte
residence times (s)
2.39

Leukocyte
residence times (s)
2.39

Difference in
residence times (s)
0

50

2.39

2.41

0.02

100

2.4

2.47

0.07

150

2.41

2.57

0.16

200

2.42

2.74

0.32

250 (nominal)

2.43

2.98

0.55

300

2.45

3.34

0.89

350

2.46

3.93

1.47

400

2.49

4.96

2.47

450

2.51

7.35

4.84
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Variation in chamber rotation frequency
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Figure 6.13: Graph of chamber rotation frequency versus residence time of leukocytes and erythrocytes. The
difference between residence times start off the same at low chamber rotations, but as the rotation frequency
increases, the difference in residence times increase as well. This suggests that better separations occur at higher
rotation frequencies.
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6.8: Effect of changing the chamber distance from the axis of rotation
The distance of the center of the chamber from the axis of rotation was another
parameter that we looked at. We varied the distance from 0.052 meters to 0.252 meters.
The effect of chamber distance on residence times is shown in table 6.7 and figure 6.11.
Results were very similar to the results of the chamber rotation frequency tests. As the
chamber distance increased, the difference in residence times increased. This makes
sense because increasing the chamber distance increases the centrifugal force term (3rd
term in Equation 16).
Table 6.7: Table showing the effect of varying chamber distance on residence times

R (m)
0.052

Erythrocyte
residence times (s)
2.41

Leukocyte
residence times (s)
2.57

Difference in
residence times (s)
0.16

0.102

2.42

2.76

0.34

0.152 (nominal)

2.43

2.98

0.55

0.202

2.44

3.24

0.8

0.252

2.45

3.55

1.1

Variation in chamber distance from axis of rotation
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Figure 6.14: Graph of chamber distance versus residence time of leukocytes and erythrocytes. As the distance from the
axis of rotation increases, the difference in residence times increases as well.
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6.9: Effect of changing elutriation buffer flowrate
Finally, we looked at how changing the flowrate of the elutriation buffer affected the
residence times of the leukocytes and erythrocytes. Elutriation buffer flowrate was varied from
40 to 140 mL/min. The results of these trials are found in table 6.8 and figure 6.12. As the
flowrate of buffer increased, the difference in residence times decreased. This suggests that the
best separations occur at low flowrates.
Table 6.8: Table showing the effect of varying elutriation buffer flowrate on residence times

Q (mL/min)
40

Erythrocytes
residences times (s)
6.24

Leukocyte
residence times (s)
12.2

Difference in
residence times (s)
5.96

60

4.11

6.02

1.91

80

3.07

4.02

0.95

100 (nominal)

2.43

2.98

0.55

120

2.03

2.4

0.37

140

1.74

2

0.26

Variation in elutriation buffer flowrate
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Figure 6.15: Graph of elutriation buffer flowrate versus residence time of leukocytes and erythrocytes. As the buffer
flowrate increases, the difference in residence times decreases. This suggests that better separations occur at low
flowrates.
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6.10: Determining the optimal operating protocol
From the previous modeling trials, we were able to determine a set of conditions to
optimally operate counterflow centrifugal elutriation (CCE). We decided to vary the elutriation
buffer flowrate and keep the rest of the parameters at standard operating conditions. Two settings
are to be used, a low flowrate setting where the red blood cells are eluted followed by a high
flowrate setting where the remaining leukocytes are eluted. Our model determined that 20
mL/min was a key flowrate. At this flowrate, erythrocytes flowed through the chamber with an
average residence time of 13 seconds, as shown by figure 6.13 and figure 6.14. In contrast, figure
6.15 and figure 6.16 show that leukocytes become held up within the chamber. This is indicated
by the positive values for displacement and velocity. The positive values mean that the
leukocytes will remain at the chamber inlet while the erythrocytes will be eluted. Once the
erythrocytes have been eluted, the buffer flowrate will be increased to 60 mL/min. At this
flowrate, the remaining leukocytes should be eluted with an average residence time of six
seconds (table 6.8). Thus, the CCE should first be run at 20 mL/min for a minute, then the CCE
should be run at 60 mL/min for a minute to achieve the best separation between leukocytes and
erythrocytes.
In summary, by modeling counterflow centrifugal elutriation, we determined a protocol
that would increase the efficiency of separation between erythrocytes and leukocytes. This would
help to decrease the failure rate of the procedure, which would increase the profitability of the
overall process. The effect of this modification will be analyzed in the following profitability
analysis.
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Figure 6.16: Displacement versus time for erythrocytes at a flowrate of 20 mL/min
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Figure 6.17: Velocity versus time for erythrocytes at a flowrate of 20 mL/min
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Figure 6.18: Displacement versus time for leukocytes at a flowrate of 20 mL/min
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Figure 6.19: Velocity versus time for leukocytes at a flowrate of 20 mL/min
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Chapter 7: Unit descriptions
7.0: Major unit descriptions
7.0.0: COBE Spectra (PC-2)
A COBE Spectra Apheresis System is a commonly used therapeutic apheresis machine
that allows high degree of customization. It uses a centrifugal technology to divide the whole
blood into its major components. When the blood sample is collected from the patient in one of
the clinics, a blood from a patient is continuously running through the machine, specific
components are collected or removed from the sample, and the remaining components are
returned to the patient. A total of 8 to 12 liters of whole blood is processed until at least 5×109
white blood cells are collected. The vendor of the product is TerumoBCT.
7.0.1: Elutra® (P-02)
An Elutra® Cell Separating System is a semi-automatic counter-flow elutriation
instrument with multiple user-defined profiles, and it can separate a blood sample into multiple
fractions according to the size of cell components. A counter-flow centrifugal elutriation
technology is used, in which a centrifugal force is applied opposite to the flow direction of
media. While the chamber is rotated in a centrifuge, cells are loaded into a chamber at a flow
rate. When the flow rate is changed, the cell components are separated and come out through the
chamber by their sizes, smaller components first. We will process 450 ml of blood sample mixed
with 150mL of buffer solution at 20mL/min for 1 minute and 60mL/min for 1 minute at 2400
RPM for optimal separation of red blood cells from the white blood cells. The device can be
purchased from Terumo BCT® for $55,000.
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7.0.2: Cell Saver® 5+ (P-03, P-08)
A Cell Saver® 5+ Autologous Blood Recovery System is a blood recovery system using

Latham bowl centrifuge technology invented by Haemonetics. Latham bowl technology uses
centrifugal forces to separate red blood cells, white blood cells, and plasma and platelets by their
weights. After elutriation, a Cell Saver is used to wash out remaining platelets and some red
blood cells in the sample to increase white blood cell purity. After cell culture and expansion,
Cell Saver is used to reduce volume of the sample and increase purity of t cell by removing gene
vectors and media waste. The device can be purchased from Haemonetics® for $18,500.
7.0.3: CliniMACS® (P-04)
A CliniMACS® is an electromechanical device for isolating specific cells via magnetic
force in a closed and sterile system. A magnetic microbeads are used to label suppressor T cell
(CD4+). A magnetic field is applied to remove suppressor t cell, and the remaining sample is
washed out with buffer and elutriated.

7.0.4: Gas permeable bag (P-05)
A MACS® GMP Cell Culture Bag is a cell culturing bag that is gas-permeable and
transparent for microscopic analysis. The bag is for single use and is sterile for connections. A
60ml of the cell concentrates are cultured with 1000mL of t-cell culture media for 3 to 5 days in
a stationary bag.
7.0.5: WAVE Bioreactor™ 2/10 (P-06)
A WAVE Bioreactor™ 10/20 is a cell culturing instrument. A culture medium and the
cell sample are loaded into a single-use, sterile Cellbag, and the Cellbag is placed on a rocking
motion. The rocking motion induces a wave within the fluid, which provides efficient mixing
and gas transfer. A cell culture from the gas permeable bag is transferred to a WAVE Bioreactor
for further expansion of T cell.
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7.0.6: MaxSep (P-07)
MaxSEP® Magnetic Cell Separator is used to remove the CD3/28 dynabeads that are
within the cell culture. The MaxSEP consists of a tray with strong magnet imbedded underneath.
When a bag filled with the dynabeads is placed on tray, the beads stick to the tray and media can
then be removed from the bag. After all media has been disposed of, the magnet in the tray can
be turned off and the beads will be released for disposal.

7.1: Additional equipment descriptions

7.1.0: Ventilation systems
A ventilation system is required for a facility to ensure biosafety and sanitation. A
handling of the blood samples and biomass should be under the bench with a ventilation hood. A
ventilation hood will be required for each of the cell processing room and media preparation
room. A 4-ft and 6-ft laminar flow hood can be purchased from Air Science for $1,000 and
$1,600 respectively. For the entire facility, 10 4-ft laminar flow hood and 24 6-ft laminar flow
hood is desired. Air particles in the ventilation system are monitored by an air particle samplers
and counters. Four total air particle counters can be purchased from Lighthouse for $1000 each,
and 2 viable air particle samplers can be purchased from Beckman Coulter® for $1700 each.

7.1.1: Incubators
Incubators are used to maintain optimal conditions for the cell cultures while they are in
the cell processing rooms. A desired temperature and carbon dioxide concentration can be set
and maintained. For the entire facility, 34 HEPA filtered CO2 Incubators can be purchased from
Sanyo for $1,500 per device and 4 table-top CO2 Incubators can be purchased from Sanyo® for
$5,000 per device.
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7.1.2: Centrifuges
The centrifuges are used in various occasions to spin down cell cultures or samples. Two
small capacity (4x145mL), bench-top centrifuges, SorvallTM Biofuge PrimeTM R Benchtop
centrifuges, can be purchased for $3381 per device, 22 medium-capacity (4 x 750ml) bench top
centrifuges, SorvallTM LegendTM RT Centrifuges for $8774 per device, and 4 large-capacity (6 x
1400mL) centrifuges, SorvallTM RC-3B Plus High Capacity Centrifuge, can be purchased for
$5000 per device, all from Thermo Scientific®. These centrifuges can be refrigerated as needed.
For smaller volume, microcentrifuges can be used. Total 22 microcentrifuges, LSE™ Mini
Microcentrifuge, can be purchased from Corning® for $300 per device.

7.1.3: Refrigeration
A liquid nitrogen freezer is used to store the cells. For the entire facility, 22 liquid
nitrogen freezers can be purchased for $25,000 per device from LABRepco®. A liquid nitrogen
manifold changeover, which controls the amount of liquid nitrogen distributed to the freezers
from the tank, can be purchased from Airgas for $3353 per device. Additionally, a controlled rate
freezer is required to ensure cell viability for low temperature freezing. A controlled rate freezer
can be purchased from True® for $20336, and 10 freezers are needed.
A -30°C, -40°C, -80°C freezers are needed for storage of some materials and samples.
For the entire facility, six -30°C freezers, two -40°C freezers, and eight -80°C freezers will be
purchased from True® for $9500 each.
Most of the materials including buffer solutions, media, and reagents will be stored in a
refrigerator. Different kinds of refrigerator will be installed based on the needs and location in
the facility. Total 28 under-counter refrigerators will be purchased from Avanti® for $700 each,
10 double door refrigerators from Custom Biogenic systems for $400 each, 4 upright
refrigerators and 2 refrigerator and freezer combos from Kenmore® for $300 and $200 each, and
4 chromatography refrigerators from Thermo Scientific® for $6625 each.
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7.1.4: Flow cytometer & cell counter
The number of cells in the sample for each step and during the cell growth and expansion
are measured using flow cytometers and cell counters. Two LSRFortessaTM and two
FACSCaliburTM can be purchased from BD Biosciences for $1165 and $29500 per device.
A MultisizerTM 3 Coulter Counter device can be purchased from Beckman Coulter® for $5000
and the device can measure the number, volume, mass, and surface size distributions in one
measurement. Total 8 units of the device will be purchased.

7.1.5: Blood culturing system
A blood culturing system is a very precise instrument for detecting biological growth
within a sample of blood. This is essential when monitoring the growing cells in the bioreactor.
A blood culturing system from BACTEC can be purchased for $21,105.

7.1.6: Digital balance
Digital balances are used throughout the process to precisely measure out various
materials used. Mass precision is extremely important when handing media and the growth of
cells. While there are many providers of this commonly used equipment, a high quality scale can
be purchased form Taylor for $200.

7.1.7: Luminometer
A luminometer is a device that is capable of emitting and registering radiation over a
broad range of frequencies. These are useful in conducting assays of growth media as the cells
are being expanded. A luminometer may be purchased from Promega for $80.

7.1.8: Microscope
Microscopes are required for various steps of the process to observe the growing cells
and monitor for any irregularities in the process. A common vendor of microscopes is AmScope,
where a suitable one may be purchased for $350.
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7.1.9: Spectrophotometer
A spectrophotometer is used to analyze the nucleic acid and protein concentrations of the
cell sample. The device can be purchased from Thermo Scientific® for $10,000.

7.1.10: Plate washer
A plate washer is used to wash cells and beads that reside on the plate. Two plate washers
are needed and they can be purchased from Tecan® for $1000.

7.1.11: Tube connection
A disposable tubing system is used in different machines in the facility, and a sterile
procedure is required. A SebraHeat Sealer, which seals the tubes that are cut, can be purchased
from Haemonetics for $5400 each, and 44 units are needed. A sterile connecting device that
connects two tubes can be purchased from Terumo BCT® for $1500, and 30 units are needed.

7.1.12: Water bath
A water bath is used to warm up media or other reagents used for a cell culture. It can be
purchased from Thermo Scientific for $150, and 34 units are needed.
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Chapter 8: Unit specification sheets
8.0: COBE Spectra (P-C2)
COBE® Spectra Apheresis System
Description and Function A blood cell separator
To separate blood cells based on cell density and size
Manufacturer

Terumo BCT

PFD Reference

P-C2

Operation

Batch

Materials Handled

Unit

Operating Conditions

Output
(to lab)

Output
(to Patient)

cells/mL 5.20×109 4.44×108

5.42×109

White Blood Cell cells/mL 7.50×106 3.33×107

6.29×106

Granulocytes cells/mL 9.07×105 4.02×106

7.60×105

Monocytes cells/mL 1.57×106 6.98×106

1.32×106

T- cell cells/mL 4.99×106 2.22×107

4.19×106

Suppressor T-cell cells/mL 2.51×104 1.11×105

2.10×104

Platelets

cells/mL 3.50×108 1.04×109

3.17×108

Plasma

mL

5185.65

Red Blood Cell

Characteristics

Input

5430

244.35

Dimension

148cm (H) x 70cm (W) x 71cm (D)

Weight

177kg

Temperature

Room temperature

Pressure

1 atm

Duration

2-4 hours

Flow Rate

0-150 mL/min

Centrifuge Speed

400-2400 rpm
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8.1: Elutra® Cell Separating System (P-02)
Elutra® Cell Separating System
Description and
Function

Counter-flow elutriation based on cell density and size
To separates leukocytes from the blood sample

Manufacturer

Terumo BCT

PFD Reference

P-02

Operation

Batch

Materials Handled

Characteristics

Operating
Conditions

Purchase Cost

Unit

Input

Waste

Output

Red Blood Cell

cells/mL

3.33×108

3.67×108

3.33×107

White Blood Cell

cells/mL

2.50×107

1.85×107

8.27×107

Granulocytes

cells/mL

3.02×106

3.17×106

1.67×106

Monocytes

cells/mL

5.23×106

5.48×106

3.00×106

T- cell

cells/mL

1.66×107

9.80×106

7.80×107

Suppressor T-cell

cells/mL

8.33×104

9.25×104

1.30×103

Platelets

cells/mL

7.83×108

6.48×108

2.00×109

Plasma

mL

244.35

219.92

24.44

Buffer

mL

150

0

0

Model

Elutra® Cell Separating System

Dimension

180.3cm (H) x 70cm (W) x 68cm (D)

Weight

177kg

Temperature

Room temperature

Pressure

1 atm

Duration

1-2 hours

Flow Rate

0-120 mL/min

Centrifuge Speed

0-2400 rpm

$55,000
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8.2: Cell Saver 5+ (P-03, P-08)
Cell Saver® 5+ Autologous Blood Recovery System
Description and
Function

A cell-washing machine
To wash blood sample to increase purity or reduce volume

Manufacturer

Haemonetics®

PFD Reference

P-03, P-08

Operation

Batch

Materials Handled

Characteristics

Operating
Conditions

Purchase Cost

Unit

Input

Waste

Output

Red Blood Cell

cells/mL

3.33×107

2.40×106

3.33×106

White Blood Cell

cells/mL

8.27×107

3.44×106

3.97×107

Granulocytes

cells/mL

1.67×106

6.93×104

8.00×105

Monocytes

cells/mL

3.00×106

1.25×105

1.44×106

T- cell

cells/mL

7.80×107

3.24×106

3.74×107

Suppressor T-cell

cells/mL

1.30×103

2.71×101

3.13×102

Platelets

cells/mL

2.00×109

1.31×108

3.59×108

Plasma

mL

24.44

18.31

6.12

Buffer

mL

750

693

57

Model

Cell Saver® 5+ Autologous Blood
Recovery System

Dimension

94cm (H) x 40.6cm (W) x 36.8cm
(D)

Weight

32.2kg (machine), 15.9kg (cart)

Temperature

Room Temperature

Pressure

1 atm

Flow Rate

0-1000 mL/min

Centrifuge Speed

2050-5650 rpm

$18,500
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8.3: CliniMACS (P-04)
CliniMACS® Plus Instrument
Description and
Function

A magnetic cell isolation machine
To remove suppressor t-cell

Manufacturer

Miltenyi Biotec

PFD Reference

P-04

Operation

Batch

Materials Handled

Characteristics

Operating Conditions

Purchase Cost

Unit

Input

Waste

Output

Red Blood Cell

cells/mL

60

5.00×104

3.17×106

White Blood Cell

cells/mL

3.33×106

5.95×105

3.77×107

Granulocytes

cells/mL

3.97×107

1.20×104

7.60×105

Monocytes

cells/mL

8.00×105

2.16×104

1.37×106

T- cell

cells/mL

1.44×106

5.62×106

3.56×107

Suppressor T-cell

cells/mL

3.74×107

9.29×101

3.13

Platelets

cells/mL

3.13×102

5.39×106

3.23×108

Plasma

mL

3.59×108

0.31

5.82

CD4 Microbeads

mL

0.07

0

0.07

Buffer

mL

257

198

59

Model

CS2-CE/UL

Dimension

70cm (H) x 90cm (W) x 60cm (D)

Weight

35kg

Temperature

Room Temperature

Pressure

1 atm

Duration

2-6 hours

$55,000

68

8.4: Gas Permeable Bag (P-05)
MACS®GMP Cell Differentiation Bag
Description and
Function

A gas permeable bag
To grow cell culture

Manufacturer

Miltenyi Biotec

PFD Reference

P-05

Operation

Batch

Materials Handled

Characteristics

Operating Conditions

Purchase Cost

Unit

Input

Output

Red Blood Cell

cells/mL

3.17×106

1.79×105

White Blood Cell

cells/mL

3.77×107

8.13×106

Granulocytes

cells/mL

7.60×105

4.30×104

Monocytes

cells/mL

1.37×106

7.74×104

T- cell

cells/mL

3.56×107

8.01×106

Suppressor T-cell

cells/mL

3.13

1.77×10-1

Platelets

cells/mL

3.23×108

1.93×107

Plasma

mL

5.82

5.82

CD3/28 Dynabeads

beads /mL

4.00×107

3.77×104

Buffer

mL

59

59

Culture media

mL

1000

1000

Model

REF 170-076-404

Capacity (Volume)

1000mL

Temperature

37°C

Pressure

1 atm

Duration

3~5 Days

$76
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8.5: Wave Bioreactor 2/10 (P-06)
WAVE Bioreactor TM 2/10
Description and
Function

A wave-rocking bioreactor
To expand cell culture

Manufacturer

GE Healthcare Life Sciences

PFD Reference

P-06

Operation

Batch

Materials Handled

Characteristics

Operating Conditions

Purchase Cost

Unit

Input

Output

Red Blood Cell

cells/mL

1.79×105

1.90×104

White Blood Cell

cells/mL

8.13×106

6.55×106

Granulocytes

cells/mL

4.30×104

4.56×103

Monocytes

cells/mL

7.74×104

8.21×103

T- cell

cells/mL

8.01×106

6.54×106

Suppressor T-cell

cells/mL

1.77×10-1

1.88×10-2

Platelets

cells/mL

1.93×107

2.05×106

Plasma

mL

5.82

5.82

CD3/28 Dynabeads

beads /mL

3.77×104

4.00×103

Buffer

mL

59

59

Culture media

mL

9940

9940

Model

WAVE Bioreactor TM 2/10

Capacity (Volume)

10L

Temperature

37°C

Pressure

1 atm

Duration

4~6 Days

$47,500
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8.6: MaxSep (P-07)
MaxSEP Magnetic Cell Separator
Description and
Function

A magnetic separator
To remove dynabeads from the cell culture

Manufacturer

Baxter Fenwal

PFD Reference

P-07

Operation

Batch

Materials Handled

Unit

Input

Waste

Output

1.90×104

0

1.90×104

6.55×106

0

6.55×106

Red Blood Cell

cells/mL

White Blood
Cell

cells/mL

Granulocytes

cells/mL

4.56×103

0

4.56×103

Monocytes

cells/mL

8.21×103

0

8.21×103

T- cell

cells/mL

6.54×106

0

6.54×106

Suppressor Tcell

cells/mL
1.88×10-2

0

1.88×10-2

Platelets

cells/mL

2.05×106

0

2.05×106

Plasma

mL

5.82

0

5.82

CD3/28
Dynabeads

beads
/mL

4.00×103

4.00×103

Buffer

mL

59

0

59

Culture media

mL

9940

0

9940

0

Characteristics

Model

MaxSEP Magnetic Cell Separator

Operating Conditions

Temperature

Room Temperature

Pressure

1 atm

Purchase Cost

$1,165
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Chapter 9: Overall process cost for T-cell therapy
9.0: Utility costs
The primary utilities required for operating most chemical or pharmaceutical plants are
water and electricity. The requirement for water in this process is minimal, as most fluids used in
the process are sterile media or buffers. There is no requirement for cooling water as
temperatures for most of the process stay close to body temperature. Samples are typically cryopreserved immediately upon completion of the process, but this is a short process that mainly
requires careful storage of liquid nitrogen.
The cost of electricity for the process is negligible. Not requiring large columns or other
equipment, as well as the lack of any extremely high temperatures or pressures, significantly
reduces the energy requirement. The Wave Bioreactors used in expanding the cells would require
the most energy as it is the piece of equipment that is run almost continuously for the majority of
the process. However a single WAVE Bioreactor System 2/10, with a power rating of 87W,
would cost $43.85 to continuously operate for an entire working year. This is assuming a cost of
electricity at $0.07 per kWh. These utility costs, aside from those provided by the current clinical
facility, will be ignored when costing each individual treatment.
The media and other buffers used to suspend the T-cells when they are growing must be
removed before the final product is sent back to the patient. These fluids must be considered
biohazard material and disposed of appropriately. At laboratory scales the used media is
combined with bleach and dumped down the drain. The large scale production facility will likely
not be able to use this simple method to dispose of the media and will instead incur costs of 10%
of the cost of the material.
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9.1: Major process equipment costs
The initial plant will contain 20 individual cell processing rooms, capable of producing the therapy for
approximately 33 patients each year. The quantity of each equipment required can be assumed to scale
directly with the number of cell processing rooms. This assumption was also made in determining the
additional cost of expanding the facility in future years.
Table 9.1: List of major operating equipment

Component Name
MaxSep Magnetic

P-07

Quantity Vendor

Cost

8

Baxter

$1165

4

Terumo

$55000

Haemonetics

$18500

8

Miltenyi

$55000

16

GE Healthcare Life

$47500

Separators
P-02

Elutra

P-03/08

Cell Saver 5 Autologous 12
Blood Recovery
Systems
CliniMACS Magnetic

P-04

Separator
WAVE 2/10 Bioreactor

P-06

Sciences

Bare module costs will not be accounted for because all of the equipment is delivered
assembled. Aside from certain calibrations, all equipment listed in table 9.1 can be used as is.
Most of the additional equipment also do not require assembly and will exclude bare module
costs from the total capital investment. Exceptions include the laminar flow hood, however these
do not represent a significant contribution to the total cost of equipment and will be assumed as
negligible.
All costs for equipment, including the additional equipment in section 9.2 were obtained
directly from the equipment supplier websites. If a precise quote was unavailable, pricing data
was found for similar equipment from other suppliers or from bulk, industrial suppliers, such as
www.alibaba.com.
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9.2: Additional equipment costs
Table 9.2: List of additional operating equipment

Additional Equipment
Name

Quantity Vendor

Cost

4’ Laminar Flow Hood

10

Air Science

$1000

6’ Laminar Flow Hood

24

Air Science

$1600

9050 Blood Culturing System

6

BACTEC

$21105

LSRFortessa Flow Cytometer

2

BD

$1165

Calibur Flow Cytometer

2

FACS

$29500

M/M3 Cell Counter/ Sizers

8

Beckman Coulter

$5000

Digital Balance

36

Taylor Precision

$200

HEPA Filtered CO2 Incubator

34

Sanyo

$1500

LN2 Freezer

22

LABRepCo

$25000

LN2 Manifold Changeover

2

Airgas

$3353

Luminometer

2

Promega

$80

Microcentrifuge

22

Corning

$300

Biofuge primoR Centrifuge

2

Sorvall

$3381

Legend RT Centrifuge

24

Sorvall

$8774

RC3B-plus Centrifuge

4

Sorvall

$5000

Microscope

26

AmScope

$350

-30oC Freezer

6

True

$8000

-40 oC Freezer

2

True

$9500

-80 oC Freezer

8

True

$9500

Controlled Rate Freezer

10

True

$20336

Double Door Refrigerator

10

Custom Biogenic Systems

$400

Under-Counter Refrigerator

28

Avanti

$700

Upright Refrigerator

4

Kenmore

$300

Refrigerator/Freezer Combo

2

Kenmore

$200

Chromatography Refrigerator

4

Thermo Scientific

$6625

Plate Washer

2

Tecan

$1000
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Sebra Heat Sealer

32

Haemonetics

$5400

Spectrophotometer

2

Thermo Scientific

$10000

Table-top CO2 Incubator

4

Panasonic

$5000

Sterile Connecting Device

30

Terumo

$1500

Total Air Particle Counters

4

Lighthouse

$1000

Viable Air Particle Sampler

2

Beckman Coulter

$1700

Water bath

34

Thermo Scientific

$150

9.3: Building construction costs
Using data provided by the head architect of the existing clinical trial facility, a facility
with 20 cell processing rooms, including quality control, freezer rooms, office space, and
additional cGMP space requires 13,000 ft2. High specialized space like the cGMP environment
and the rest of the processing plant require extremely high construction costs and will likely be
constructed within an existing hospital network building to take advantage of HEPA filtration
capabilities and waste and consumable disposal. The construction costs for such a space will be
$800/ft2. The initial facility space will cost $10,400,000 to construct.

9.4 Individual treatment cost summary
It is easiest to calculate the costs incurred to the lab by looking at the costs of an
individual treatment. While the actual cost of each treatment varies slightly due to the fluctuation
in the volume and concentration of the blood received from the patient, a typical cost will be
used to represent the average batch for profit analysis purposes. Table 9.3 contains a list of the
specific costs that must be accounted for the production of the therapy for one patient.
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Table 9.3: List of costs incurred for single treatment

Average Process Costs
Component

Cost

Apheresis

$1500

Media

$10000

Disposal Costs

$1000

Ex-vivo Expansion

$1400

Suppressor Protein Removal

$600

Quality Control

$6000

Consumables

$800

Usage of facility (Staff/electricity)

$2700

Overhead Costs/Other

$2000
Total

$26000

9.5 Overall process costs
The total cost of equipment for a new facility with 20 cell processing rooms will be
$3,513,814. This, along with the cost of building construction, represents a capital investment
that must be depreciated. Most capital investments in the pharmaceutical industry use the
Modified Accelerated Cost Recovery System for calculating depreciation. On the 5-year model,
the subsequent years of depreciation are 20%, 24.49%, 19.2%, 11.52%, 11.52% and 5.76%.
The individual treatment cost of $26000 includes components such as electricity and staff
salaries that would typically be considered fixed costs. The current clinical facility calculates
costs in the manner displayed in table 9.3 and we will thus also consider these utilities and
services as variable costs. General fixed costs will be assumed to be 15% of the variable costs for
the first year or $2,600,000.
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Chapter 10: Economic analysis
10.0 Economic analysis
The adoptive T-cell therapy presents many advantages to the existing forms of treatment
for ALL including greater efficacy, shorter timeframe for results, fewer side effects and the
patient specificity. When used in conjunction with stem cell transplantation, this therapy has the
potential to cure virtually all cases of ALL. However, it will be unrealistic to consider the large
scale production of this therapy if it is not economically viable. An analysis of the profitability
will be used to determine how the drug should be priced as well as consider the scale-up of the
current facility to meet the demands of the patient population.

10.1 Market analysis
While there are a few research teams currently conducting clinical trials of adoptive Tcell therapy, no such therapy has yet been brought to market. The only comparable
immunotherapy that has been FDA approved is Blincyto, a drug that channels T-cells towards
CD19 expressing tumor cells. A standard course of treatment for Blincyto runs at $178,000. This
cost is exorbitantly high and would likely prohibit many patients, even those who are insured,
from utilizing this treatment. Typical costs incurred by ALL patients undergoing chemotherapy
today range from $54,587 to upwards of $126,613 (Tong, et al) for a complete course of
treatment. This price accounts for drugs, additional medication, daycare treatment (for young
patients), inpatient care, blood products, laboratory activities, and other hospital activities. The
cost of the adoptive T-cell therapy would likely be $100,000 for the complete treatment, a
reasonable price when considering the increased efficacy as well as the cost of competing
alternatives.
However it would be unrealistic to expect the new facility to be capable of treating the
entire ALL patient population in the geographic area. The primary determinant of the production
capability of the facility is the number of cell processing rooms. Each cell processing room can
handle a single patient at a time and typically takes nine days per patient. The facility operates
300 days a year with most capacity during the standard hours of 9am to 5pm, while the WAVE
bioreactors are monitored and running throughout the night. The initial plant will contain twenty
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cell processing rooms to reduce the upfront capital investment as well as reduce the risk
associated with introducing a new product to the market. If unforeseen issues with production of
the treatment arise, there will be less capital at stake. It is expected that every three years, for the
life of the twelve year process, an additional ten cell processing rooms will be added to the
facility, resulting in fifty rooms in the final three years.
An initial facility with a larger capacity was not built, because it would be difficult to
justify the almost doubling of initial capital costs for marginal increase in the net present value.
Particularly in an industry as volatile as the healthcare payer industry, beginning with a smaller
facility would be advisable.
The first year of production with the new facility will have the capacity to produce the
treatment for 667 patients, although clinical trial data indicates it is likely that approximately
10% of the batches will fail due to unforeseen problems with growing the cells or the patient
dying before the treatment is completed, but will still incur the costs of production. This typically
occurs when the separation equipment is unable to obtain a large enough concentration of the
desired T-cells. We expect that this percentage will decrease to 5% by the seventh year as the
team gains experience with the process and minimizes all potential sources for error. In the
optimization of the Elutra Cell Separating System, we expect that the proper utilization of our
designed operating conditions will be able to significantly reduce the chance of a faulty
separation to a 1% failure rate. In the economic analysis data presented in the appendix, we
consider both operating scenarios (1% failure versus a transition from 10% to 5%).
Using these production specifications, the facility will attempt to treat 667 patients in the
first year and a total of 14,000 patients over the course of the twelve years.

10.2 Profitability analysis
A cost of capital of 15% and a corporate tax rate of 35% were used to calculate important
profitability information. The interest rate was not higher, because the risk associated with this
product should not be particularly high, given the extremely promising results from clinical
trials.
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For the operation of the facility with the Elutra settings currently used, the Net Present
Value (NPV) for the 12 year project is $214,821,709. The Internal Rate of Return (IRR) on such
a facility would be 300.01% and the Return on Investment (ROI) would be 138.47%. All three of
these numbers indicate that the project would be good investments and could potentially lead to a
successful company. Using a 15% Cost of Capital, the product pricing that will lead to an NPV
of 0 is $33,884. This product pricing for a “15% company” would be significantly lower than
competitor products. At a fraction of the cost of other alternatives, the adoptive T-cell therapy
has the potential to almost guarantee a complete remission of ALL.
While some insurance companies may attempt to avoid completing claims filed for novel
therapies, such as the adoptive T-cell therapy, this is relatively easily dealt with. Most health
insurance companies, when provided with reports documenting the efficacy of the treatment for
the particular form condition, along with statements from medical professionals, will agree to
cover the treatment (American Cancer Society)1.
The utilization of our design protocol for the Elutra will only increase the appeal of this
process. By improving the separation of the sample, the chance of failure would decrease. When
each failed treatment results in a direct loss of revenue, this design result has the potential to
improve all of the financial identifiers. The designed facility would have an NPV of
$238,742,275, or $23,920,566 more than the current facility conditions. The IRR would also be
343$ and the ROI 158.04%.

10.3 Sensitivity analysis
A sensitivity analysis was conducted on three factors: the price of the product, the cost of
production for a treatment, and the failure rate for the process. The results of this analysis are
presented in the appendices, but will be summarized here. A comparison of the effects that
variations in the price of the product and the failure rate can have on the NPV shows a large
range of NPV values for the observed scenarios. While the failure rate varies from 10% to 0%,
the NPV fluctuates from $410.5 million all the way up to an impressive $418 million. However,
trends in the data show that even increases of 2-3% on the failure rate could drop the NPV of the
project by several million dollars. The price of the product has a potentially even larger effect on
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the NPV. Regardless, it does not seem likely that the NPV could drop below $0, so it is safe to
say that this will be an advisable investment.
In the second sensitivity analysis, the variable costs per treatment were varied at a given
failure rate of 1%, as expected from the newly designed Elutra. Both the product price and
production costs were varied within ±50% of the original value, and all resulting NPV values
remained above zero. However at low prices and high costs the NPV drops as low as $110.5
million, with the product price having the stronger influence on the NPV.
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10.4: Chapter 4 References
1. Paying for chemo treatment. (2014, August 24). Retrieved April 14, 2015, from
http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/
under-chemotherapy-paying-for-chemo
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Chapter 11: Conclusions and recommendations
The proposal for an adoptive T-cell therapy facility details the process currently being
performed in clinical trials at the Hospital of the University of Pennsylvania under a team led by
Dr. Bruce Levine. The therapy specifically treats acute lymphoblastic leukemia by reengineering
the patient’s own T-cells to specifically target the tumor cells. Success of the treatment relies on
a successful separation and re-concentration of the patient’s white blood cells before the
modifications are made using certain gene vectors. A WAVE bioreactor is utilized to expand all
transformed cells to concentrations large enough for injection back into the host patient. The
facility can exist in collaboration with external clinics where apheresis is conducted and blood
products are transferred to the main processing center. Proper production of the treatment must
be conducted within cGMP conditions, which require specialized facility construction and
regulation.
To improve the success rate of the overall procedure, we first identified a step in the
process that was largely responsible for process failure. This step was the separation of
erythrocytes from leukocytes. By modeling counterflow centrifugal elutriation, we were able to
determine how various operating parameters, such as rotation frequency, buffer flowrate, and
buffer density, affected the residence times of leukocytes and erythrocytes. Through Matlab
simulations, we found an ideal operating condition that would essentially provide a perfect
separation between erythrocytes and leukocytes with a difference in average residence times of
infinity. This led us to propose an operating procedure for CCE, which was to first run the
separation at 20 mL/min for one minute, then increase the flowrate and run the separation at 60
mL/min for another minute. We estimate that our proposed protocol will reduce the failure rate
from 10% to 1%, increasing the overall profitability of the procedure.
This therapy will be the first of its kind to obtain FDA approval. The only other
immunotherapy currently on the market is a drug that costs $178,000 per treatment and has
shown almost half the efficacy of the T-cell treatment. At a cost of $100,000 this therapy would
be priced competitively with other existing options for patients with severe ALL. The proposed
facility will attempt to treat a significant portion of the ALL population located in the Northeast
region of the United States. Assuming a typical patent life, the product will have a 12 year life82

span. Beginning with a smaller facility to reduce initial capital costs and minimize financial risk,
the facility will treat approximately 667 patients annually, but will scale-up every three years to
treat up to 1667 patients per year for its last three years of operation. Utilizing the results from
the Elutra design, the failure rate of the process should be minimized to 1% per year. Using all
economic data available about the current process, the NPV, IRR and ROI for the designed
facility would be $238,742,275, 343% and 158.04%, respectively. This would represent a more
than $23 million increase in the NPV from a facility operating under the existing conditions. All
three of these values indicate that the proposed facility would be an excellent investment
opportunity.
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Appendix A: Stoichiometry of animal cell growth
C6H12O6 + pC5H10O3N2 + qO2 → rCH1.82O0.84N0.25 + sC3H3O3 +tNH3 +uCO2 + vH2O
Molecular Formula
C6H12O6
C5H10O3N2
O2
CH1.82O0.84N0.25
C3H3O3
NH3
CO2
H2O

Name
Glucose
Glutamine
Oxygen
Biomass (t-cell)
Lactic Acid
Ammonia
Carbon Dioxide
Water
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Coefficient
p
q
r
s
t
u
v

1
0.52
1.64
1.52
1.80
0.66
1.67
0.82

Appendix B: Sample calculations
Calculation of sphericity of erythrocyte
Volume of erythrocyte = ¼ π * t * D2 = ¼ π * 2 * 72 = 76.97 μm3
Diameter of sphere = (6 * volume of erythrocyte * (1/π))1/3 = (6 * 76.97 * (1/π))1/3 = 5.28 μm
Surface area of sphere = πD2 = π(5.28)2 = 87.5 μm2
Surface area of erythrocyte = ½ π D2 + πDt = ½ * π * (7)2 + π * (7) * 2 = 120.95 μm2
Sphericity = 87.5/120.95 = 0.723
Calculation of Sauter mean diameter
Vp = ¼ π D2 * t = ¼ π 72 * 2 = 77.0 μm3
Ap = ½ π D2 + πDt = ½ * π * (7)2 + π * (7) * 2 = 120.95 μm2
dsd = 6 * (Vp/Ap) = 3.82 μm
Calculation of effective diameter
deff = dsd * sphericity = 0.723 * 3.82 = 2.76 μm
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Appendix C: Matlab script
%TubeODE45
%%Function
function output=tube(t,r);
mp=1.21e-14;
mu=6.53e-4;
Dp=2.76e-6;
pp=1100;
pf=1000;
omega=251;
D=0.00714;
R=0.152;
Ro=0.102;
Ri=0.202;
Q=-1.67e-6;
Uf=Q/(pi()*(D/2)^2);
A=(3*pi()*mu*Dp)/mp;
B=((pi()/6)*Dp^3*(pp-pf)*omega^2)/mp;
C=(3*pi()*mu*Dp*Uf)/mp;
output=zeros(2,1);
output(1)=r(2);
output(2)=-A*r(2)+B*r(1)+C;
end
%%RunningCode
clear all;
time_period=[0 10];
Ri=0.202;
initial=[Ri,0];
[t,r]=ode45(@tube,time_period,initial)
plot(t,r(:,1)), title('displacement')
xlabel('time(s)')
ylabel('r(m)')
figure
plot(t,r(:,2)), title('velocity')
xlabel('time(s)')
ylabel('velocity(m/s)')
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(28,600,000.00) $
(37,266,667.00) $
(37,266,667.00) $
(37,266,667.00) $
(45,933,333.00) $
(45,933,333.00) $
(45,933,333.00) $

(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $

(6,956,907.00) $ (26,000,000.00) $
$ (34,666,667.00) $
$ (34,666,667.00) $
(6,956,907.00) $ (34,666,667.00) $
$ (43,333,333.00) $
$ (43,333,333.00) $
2,003,589.22 $ (43,333,333.00) $

$ 90,000,000.00 $
$ 126,635,000.00
$ 126,635,000.00
$ 126,635,000.00 $
$ 158,333,650.00
$ 158,333,650.00
$ 158,333,650.00 $

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

60%

80%

80%

80%

100%

100%

100%

2022

2023

2024

2025

2026

2027

2021

(28,600,000.00) $

(2,600,000) $

$ (26,000,000.00) $

$ 90,000,000.00

$26,000.00

60%

2020

(28,600,000.00) $

(2,600,000) $

$ (26,000,000.00) $

$ 90,000,000.00

$26,000.00

60%

(19,933,333.50) $

2019

(19,933,333.50) $

(2,600,000) $

$ 60,000,300.00 $

$26,000.00

40%

2018

(2,600,000) $

$ (17,333,333.50) $

$ 60,000,300.00

$26,000.00

40%

2017
(6,956,907.00) $ (17,333,333.50) $

(19,933,333.50) $

(2,600,000) $

$ (17,333,333.50) $

(13,913,814.00)

Total Costs

$ 60,000,300.00

Fixed Costs

$26,000.00

Var Costs

0%

$

Capital Costs

40%

Sales

2016

Percentage of Product Unit
Price
Design Capacity

2015

Year

Cash Flow Summary

D1: Cash Flow Summary for Current Design

Appendix D: Profitability analysis calculations

2,782,762.80
4,452,420.48
2,671,452.29
2,994,252.77
3,829,081.61
2,137,161.83
2,192,817.09
3,027,645.93
1,736,443.99
2,192,817.09
3,027,645.93
1,736,443.99

Depreciation

50,086,022
73,503,885
94,012,514
109,635,112
131,761,601
151,097,545
166,497,513
184,746,589
200,678,155
214,690,639

40,957,988
41,250,179
36,136,017
58,856,902
59,149,093
54,175,182
73,827,692
74,119,882
74,970,294

20,442,012
20,149,821
18,307,076
30,511,431
30,219,240
28,236,244
38,572,625
38,280,435
39,433,612

58,405,747
57,570,918
52,305,931
87,175,516
86,340,687
80,674,982
110,207,500
109,372,671
112,667,462

35,320,478
22,456,547

27,601,875
10,653,513

12,465,091
35,614,546
30,438,607

(9,043,979)
14,449,495

(9,043,979)
27,017,495
13,049,471

Cumulative Net
Net Earnings Present Value at 15%
37,284,204

Taxes
(13,913,814) (4,869,835)

Taxible Income
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(19,933,333.50) $
(19,933,333.50) $
(19,933,333.50) $
(28,600,000.00) $
(28,600,000.00) $
(28,600,000.00) $
(37,266,667.00) $
(37,266,667.00) $
(37,266,667.00) $
(45,933,333.00) $
(45,933,333.00) $
(45,933,333.00) $

(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $
(2,600,000) $

$ (17,333,333.50) $
$ (17,333,333.50) $
(6,956,907.00) $ (17,333,333.50) $
$ (26,000,000.00) $
$ (26,000,000.00) $
(6,956,907.00) $ (26,000,000.00) $
$ (34,666,667.00) $
$ (34,666,667.00) $
(6,956,907.00) $ (34,666,667.00) $
$ (43,333,333.00) $
$ (43,333,333.00) $
2,003,589.22 $ (43,333,333.00) $

$ 66,000,330.00
$ 66,000,330.00 $
$ 99,000,000.00
$ 99,000,000.00
$ 99,000,000.00 $
$ 131,967,000.00
$ 131,967,000.00
$ 131,967,000.00 $
$ 165,000,330.00
$ 165,000,330.00
$ 165,000,330.00 $

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

$26,000.00

40%

40%

60%

60%

60%

80%

80%

80%

100%

100%

100%

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

(13,913,814.00)

Total Costs

$ 66,000,330.00

Fixed Costs

$26,000.00

Var Costs

0%

$

Capital Costs

40%

Sales

2016

Percentage of Product Unit
Price
Design Capacity

2015

Year

Cash Flow Summary

D2: Cash Flow Summary for Improved Design

2,782,762.80
4,452,420.48
2,671,452.29
2,994,252.77
3,829,081.61
2,137,161.83
2,192,817.09
3,027,645.93
1,736,443.99
2,192,817.09
3,027,645.93
1,736,443.99

Depreciation

(9,043,979)
17,840,816
41,660,775
58,990,645
85,753,264
109,170,377
127,322,091
150,751,503
171,220,423
187,605,587
206,925,800
223,788,789
238,611,205

(9,043,979)
30,917,515
31,501,895
26,356,566
46,807,988
47,100,179
41,986,017
62,322,702
62,614,893
57,640,982
78,161,034
78,453,224
79,303,636

15,149,482
14,565,102
12,753,523
23,592,012
23,299,821
21,457,076
32,377,631
32,085,440
30,102,444
40,905,963
40,613,773
41,766,950

41,614,576
36,438,637
67,405,747
66,570,918
61,305,931
92,507,516
91,672,687
86,006,982
116,874,180
116,039,351
119,334,142

Cumulative Net
Net Earnings Present Value at 15%

43,284,234

Taxes

(13,913,814) (4,869,835)

Taxible Income

D3: Profitability Measures for Current Design
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D4: Profitability Measures for Improved Design
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10.00%
48,466,975
80,179,524
111,892,073
143,604,622
175,317,170
207,029,719
238,742,268
270,454,816
302,167,365
333,879,914
365,592,462

9.00%
50,228,784 $
82,293,694 $
114,358,604 $
146,423,515 $
178,488,425 $
210,553,335 $
242,618,246 $
274,683,156 $
306,748,067 $
338,812,977 $
370,877,887 $

8.00%
51,990,592 $
84,407,864 $
116,825,136 $
149,242,408 $
181,659,680 $
214,076,952 $
246,494,224 $
278,911,496 $
311,328,768 $
343,746,040 $
376,163,312 $

7.00%
53,752,400 $
86,522,034 $
119,291,668 $
152,061,301 $
184,830,935 $
217,600,569 $
250,370,202 $
283,139,836 $
315,909,469 $
348,679,103 $
381,448,737 $

6.00%
55,514,209 $
88,636,204 $
121,758,199 $
154,880,194 $
188,002,190 $
221,124,185 $
254,246,180 $
287,368,176 $
320,490,171 $
353,612,166 $
386,734,162 $

90,750,374 $
124,224,731 $
157,699,088 $
191,173,445 $
224,647,802 $
258,122,159 $
291,596,515 $
325,070,872 $
358,545,229 $
392,019,586 $

92,864,544 $
$
$
$
$
$
$
$
$
$

126,691,262
160,517,981
194,344,699
228,171,418
261,998,137
295,824,855
329,651,574
363,478,293
397,305,011

94,978,714 $
129,157,794 $
163,336,874 $
197,515,954 $
231,695,035 $
265,874,115 $
300,053,195 $
334,232,275 $
368,411,356 $
402,590,436 $

97,092,883 $
131,624,325 $
166,155,767 $
200,687,209 $
235,218,651 $
269,750,093 $
304,281,535 $
338,812,977 $
373,344,419 $
407,875,861 $

99,207,053 $
134,090,857 $
168,974,661 $
203,858,464 $
238,742,268 $
273,626,071 $
308,509,875 $
343,393,678 $
378,277,482 $
413,161,285 $

101,321,223 $

136,557,389 $

171,793,554 $

207,029,719 $

242,265,884 $

277,502,049 $

312,738,215 $

347,974,380 $

383,210,545 $

418,446,710 $

$60,000 $

$70,000 $

$80,000 $

$90,000 $

$100,000 $

$110,000 $

$120,000 $

$130,000 $

$140,000 $

$150,000 $

5.00
57,276,017 $

59,037,825 $

60,799,633 $

62,561,442 $

64,323,250 $

66,085,058 $

$50,000 $

Failure Rate
$

4.00%

3.00%

2.00%

1.00%

.00%

Sensitivity Analyses (NPV)

D5: Sensitivity Analysis to Failure Rate of Process

Product Price
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$150,000 $ 458,971,002

$140,000 $ 424,087,198

$130,000 $ 389,203,395

$120,000 $ 354,319,591

$110,000 $ 319,435,788

$100,000 $ 284,551,984

$90,000 $ 249,668,180

$80,000 $ 214,784,377

$70,000 $ 179,900,573

$60,000 $ 145,016,770

$50,000 $ 110,132,966

$13,000

Sensitivity Analyses (NPV)

$
$
$
$
$
$
$
$
$
$
$

100,971,023
135,854,826
170,738,630
205,622,434
240,506,237
275,390,041
310,273,844
345,157,648
380,041,451
414,925,255
449,809,059

$15,600

$ 91,809,080
$ 126,692,883
$ 161,576,687
$ 196,460,490
$ 231,344,294
$ 266,228,097
$ 301,111,901
$ 335,995,705
$ 370,879,508
$ 405,763,312
$ 440,647,115

$18,200

$ 82,647,136
$ 117,530,940
$ 152,414,743
$ 187,298,547
$ 222,182,351
$ 257,066,154
$ 291,949,958
$ 326,833,761
$ 361,717,565
$ 396,601,368
$ 431,485,172

$20,800

$ 73,485,193
$ 108,368,997
$ 143,252,800
$ 178,136,604
$ 213,020,407
$ 247,904,211
$ 282,788,014
$ 317,671,818
$ 352,555,622
$ 387,439,425
$ 422,323,229

26,000.00

$ 64,323,250
$ 99,207,053
$ 134,090,857
$ 168,974,661
$ 203,858,464
$ 238,742,268
$ 273,626,071
$ 308,509,875
$ 343,393,678
$ 378,277,482
$ 413,161,285

$

$28,600

$ 55,161,307
$ 90,045,110
$124,928,914
$159,812,717
$194,696,521
$229,580,324
$264,464,128
$299,347,932
$334,231,735
$369,115,539
$403,999,342

Variable Costs/Treatment
$23,400

D6: Sensitivity Analysis to Cost of Production

Product Price

$31,200

$ 45,999,363
$ 80,883,167
$ 115,766,970
$ 150,650,774
$ 185,534,578
$ 220,418,381
$ 255,302,185
$ 290,185,988
$ 325,069,792
$ 359,953,595
$ 394,837,399

$33,800

$ 36,837,420
$ 71,721,224
$ 106,605,027
$ 141,488,831
$ 176,372,634
$ 211,256,438
$ 246,140,241
$ 281,024,045
$ 315,907,849
$ 350,791,652
$ 385,675,456

$36,400

$39,000

$ 376,513,512 $ 367,351,569

$ 341,629,709 $ 332,467,766

$ 306,745,905 $ 297,583,962

$ 271,862,102 $ 262,700,158

$ 236,978,298 $ 227,816,355

$ 202,094,495 $ 192,932,551

$ 167,210,691 $ 158,048,748

$ 132,326,887 $ 123,164,944

$ 97,443,084 $ 88,281,141

$ 62,559,280 $ 53,397,337

$ 27,675,477 $ 18,513,533

Appendix E: Vendor specification sheets and MSDS
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